Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial

Publication date: Available online 26 January 2015 Source:The Lancet Author(s): Michel Azizi , Marc Sapoval , Philippe Gosse , Matthieu Monge , Guillaume Bobrie , Pascal Delsart , Marco Midulla , Claire Mounier-Véhier , Pierre-Yves Courand , Pierre Lantelme , Thierry Denolle , Caroline Dourmap-Collas , Hervé Trillaud , Helena Pereira , Pierre-François Plouin , Gilles Chatellier Background Conflicting blood pressure-lowering effects of catheter-based renal artery denervation have been reported in patients with resistant hypertension. We compared the ambulatory blood pressure-lowering efficacy and safety of radiofrequency-based renal denervation added to a standardised stepped-care antihypertensive treatment (SSAHT) with the same SSAHT alone in patients with resistant hypertension. Methods The Renal Denervation for Hypertension (DENERHTN) trial was a prospective, open-label randomised controlled trial with blinded endpoint evaluation in patients with resistant hypertension, done in 15 French tertiary care centres specialised in hypertension management. Eligible patients aged 18–75 years received indapamide 1·5 mg, ramipril 10 mg (or irbesartan 300 mg), and amlodipine 10 mg daily for 4 weeks to confirm treatment resistance by ambulatory blood pressure monitoring before randomisation. Patients were then randomly assigned (1:1) to receive either renal denervation plus an SSAHT regimen (renal denervation group) or the same SSAHT alone (control group). Th...
Source: The Lancet - Category: Journals (General) Source Type: research